Significant correlation between treatment-associated molecular changes and PASI improvement was observed in the risankizumab treated patients.The efficacy, safety and tolerability was further investigated in a phase III program comprising four clinical trials which compared risankizumab to ustekinumab, adalimumab and placebo in the indication of plaque psoriasis. The results of these trials confirmed the efficacy and tolerability of risankizumab. History
Risankizumab was approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe plaque psoriasis in April 2019.The FDA approved risankizumab based on evidence primarily from five clinical trials (Trial 1/NCT0202684370, Trial 2/NCT02684357, Trial 3/NCT02672852, Trial 4/ NCT02694523 and Trial 5/NCT02054481) of 1606 patients with moderate to severe plaque psoriasis. The trials were conducted in Asia, Canada, Europe, Mexico, South America, and the United States. References
External links
"Risankizumab". Drug Information Portal. U.S. National Library of Medicine.
Telmisartan/hydrochlorothiazide, sold under the brand name Micardis HCT among others, is a fixed-dose combination medication used to treat high blood pressure. It is a combination of telmisartan an angiotensin II receptor antagonist with hydrochlorothiazide a diuretic. It may be used if telmisartan by itself is not sufficient. It is taken by mouth.Common side effects include dizziness, upper respiratory tract infections, nausea, diarrhea, and tiredness. Severe side effects may include kidney problems, electrolyte problems, and allergic reactions. Use during pregnancy may harm the baby. Telmisartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by decreasing the kidneys ability to retain water.The combination was approved for medical use in the United States in November 2000, and in the European Union in April 2002. The combination is on the World Health Organizations List of Essential Medicines. It is available as a generic medication. References
External links
"Hydrochlorothiazide mixture with telmisartan". Drug Information Portal. U.S. National Library of Medicine.